- Poster presentation
- Open Access
Software-supported analysis of MRgFUS therapy outcome
© Corr et al; licensee BioMed Central Ltd. 2015
Published: 30 June 2015
Recently, first studies on MRgFUS for therapy of localized prostate cancer have been presented. However, MRI is not only useful to monitor and guide FUS prostate cancer therapy but might add valuable morphologic and functional information for therapy stratification and outcome. Since multi-parametric MR protocols are time-consuming to generate and evaluate, they are not performed during an MRgFUS session.
Rather these data are acquired before MRgFUS for therapy planning and after therapy for outcome assessment. This approach leads to a plethora of MR images (before, during and after therapy) that can be difficult to analyze and correlate. To support the radiologist, a software prototype was therefore developed to analyze MRgFUS therapy outcome based on image registration and synchronization.
Additionally, ROIs can be placed and tracked on follow-up images or across modalities to better discriminate between tumor recurrence and scar formation in suspicious areas. MR thermometry temperature maps can be imported as well to correlate the applied thermal dose with post-therapeutic image changes. Furthermore, contrast-enhanced images acquired at the end of a therapy session can be compared with diagnostic or follow-up images to check if all affected areas were covered.
Results and conclusions
This work was supported by the BMBF, Eurostars Project E!6620 PROFUS.
This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.